Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study
Replimune presented data from its IGNYTE trial at the 2025 ASCO meeting, showing promising results for RP1, an oncolytic...
Jon Napitupulu
Xilio Announces Updated Phase 2 Data for Vilastobart
Xilio Therapeutics announced updated Phase 2 clinical trial data for vilastobart, a tumor-activated anti-CTLA-4 therapy, combined with atezolizumab, in...
Harbinger Health Showcases Early Detection at ASCO 2025
Harbinger Health unveiled clinical data for its blood-based multi-cancer early detection (MCED) test at the 2025 ASCO Annual Meeting....
Vepdegestrant Improves PFS in ESR1-Mutant Breast Cancer
Arvinas and Pfizer announced positive Phase 3 VERITAC-2 trial results for vepdegestrant, a novel oral PROTAC ER degrader for...
Voltron Therapeutics Shows Proof of Concept for VTX-0P4 in Prostate Cancer Study
Voltron Therapeutics announced positive preclinical data for VTX-0P4, a protein-based therapy, in treating prostate stem cell antigen (PSCA)-expressing cancers....
Under Treated Tardive Dyskinesia in Long-Term Care Settings
A Teva Pharmaceuticals study reveals significant gaps in the diagnosis and treatment of tardive dyskinesia (TD) among long-term care...
Teva Schizophrenia Portfolio: Uzedy® & Tev-749 Data
Teva Pharmaceuticals presented data at the 2025 Psych Congress Elevate Annual Meeting showcasing positive real-world results for UZEDY (risperidone)...
Nurexone Announces Acute Spinal Cord Injury Trial
NurExone Biologic Inc. announced that Professor Nahshon Knoller will present at the American Spinal Injury Association (ASIA) annual meeting....
Polypid’s D-Plex100: Revolutionizing Surgical Infection Prevention
PolyPid Ltd., a late-stage biopharmaceutical company, is preparing to release topline results from its phase 3 SHIELD II trial...
Syncromune® Doses First Patient in Phase 2a Trial of Sync-T® Therapy
Syncromune has dosed the first patient in its LEGION-100 Phase 2a trial for SYNC-T Therapy SV-102. This trial focuses...